COVID-19: Remdesivir to cost Nigeria, others N1m per patient
2020-06-30
Remdesivir is at the forefront of the fight against COVID-19 after it helped shorten hospital recovery times in a trial. Gilead Sciences Inc has priced its COVID-19 drug candidate Remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition fromContinue Reading